Systemic modulation of stress and immune parameters in patients treated for prostate adenocarcinoma by intensity-modulated radiation therapy or stereotactic ablative body radiotherapy

B. Frey, J. Mika, K. Jelonek, L. Cruz-Garcia, C. Roelants, I. Testard, N. Cherradi, K. Lumniczky, S. Polozov, A. Napieralska, P. Widlak, U. S. Gaipl, Christophe Badie, J. Polanska, S. M. Candéias*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Background: In this exploratory study, the impact of local irradiation on systemic changes in stress and immune parameters was investigated in eight patients treated with intensity-modulated radiation therapy (IMRT) or stereotactic ablative body radiotherapy (SABR) for prostate adenocarcinoma to gain deeper insights into how radiotherapy (RT) modulates the immune system. Patients and methods: RT-qPCR, flow cytometry, metabolomics, and antibody arrays were used to monitor a panel of stress- and immune-related parameters before RT, after the first fraction (SABR) or the first week of treatment (IMRT), after the last fraction, and 3 weeks later in the blood of IMRT (N = 4) or SABR (N = 4) patients. Effect size analysis was used for comparison of results at different timepoints. Results: Several parameters were found to be differentially modulated in IMRT and SABR patients: the expression of TGFB1, IL1B, and CCL3 genes; the expression of HLA-DR on circulating monocytes; the abundance and ratio of phosphatidylcholine and lysophosphatidylcholine metabolites in plasma. More immune modulators in plasma were modulated during IMRT than SABR, with only two common proteins, namely GDF-15 and Tim‑3. Conclusion: Locally delivered RT induces systemic modulation of the immune system in prostate adenocarcinoma patients. IMRT and SABR appear to specifically affect distinct immune components.

Original languageEnglish
Pages (from-to)1018-1033
Number of pages16
JournalStrahlentherapie und Onkologie
Volume196
Issue number11
DOIs
Publication statusPublished - 1 Nov 2020

Bibliographical note

Funding Information:
This work received funding from the European Union?s Seventh Framework Programme from the OPERRA project (Euratom/FP7) under grant agreement No. 604984 604984 and from the European Social Fund grant POWR.03.02.00-00-I029 (JM). This work has also been supported by National Science Centre, Poland NCN BiTIMS grant no. 2015/19/B/ST6/01736 (JP) and by the German Federal Ministry of Education and Research (BMBF; GREWIS-alpha, 02NUK050E) (BF and UG).

Funding Information:
This work received funding from the European Union’s Seventh Framework Programme from the OPERRA project (Euratom/FP7) under grant agreement No. 604984 604984 and from the European Social Fund grant POWR.03.02.00-00-I029 (JM). This work has also been supported by National Science Centre, Poland NCN BiTIMS grant no. 2015/19/B/ST6/01736 (JP) and by the German Federal Ministry of Education and Research (BMBF; GREWIS-alpha, 02NUK050E) (BF and UG).

Publisher Copyright:
© 2020, The Author(s).

Keywords

  • Biomarkers of radiation exposure
  • Immunophenotyping
  • Ionizing radiation
  • Prostate cancer
  • Systemic immune modulation

Fingerprint

Dive into the research topics of 'Systemic modulation of stress and immune parameters in patients treated for prostate adenocarcinoma by intensity-modulated radiation therapy or stereotactic ablative body radiotherapy'. Together they form a unique fingerprint.

Cite this